Waelbroeck M, Robberecht P, De Neef P, Christophe J
Biochem Biophys Res Commun. 1984 May 31;121(1):340-5. doi: 10.1016/0006-291x(84)90728-9.
The calcium channel antagonist verapamil is known to inhibit competitively antagonist binding to rat heart muscarinic receptors. The present data suggest that this drug recognized two binding sites on the muscarinic receptors: 1) an allosteric site modulating the tracer dissociation rates and 2) the muscarinic drug binding site. The affinity of verapamil for the allosteric site and the efficacy of its effect on muscarinic ligand dissociation rates depended on the ligand studied.
已知钙通道拮抗剂维拉帕米可竞争性抑制拮抗剂与大鼠心脏毒蕈碱受体的结合。目前的数据表明,该药物可识别毒蕈碱受体上的两个结合位点:1)一个变构位点,可调节示踪剂的解离速率;2)毒蕈碱药物结合位点。维拉帕米对变构位点的亲和力及其对毒蕈碱配体解离速率的影响效果取决于所研究的配体。